Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
November 07, 2018 09:42 ET
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
ProQR gibt positive Zwischenergebnisse aus der klinischen Phase-I/II-Studie zu QR-110 bei Patienten mit LCA10 bekannt und plant den Beginn einer Phase-II/III-Zulassungsstudie
September 05, 2018 05:46 ET
|
ProQR Therapeutics N.V.
QR-110 zeigte gemessen an Sehschärfe und Umfang der Mobilität eine schnelle und anhaltende Verbesserung des Sehvermögens bei der Mehrheit der Patienten QR-110 war gut verträglich, ohne schwerwiegende...
ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3
September 05, 2018 05:46 ET
|
ProQR Therapeutics N.V.
Le QR-110 a permis une amélioration rapide et soutenue de la vision chez la majorité des sujets, tant en termes d’acuité visuelle que de mobilité Le QR-110 a été bien toléré sans événements...
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
September 05, 2018 05:00 ET
|
Histogenics Corporation
‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After...
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
September 05, 2018 04:00 ET
|
ProQR Therapeutics N.V.
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events A...
Immuron Progresses Discussions with Institutional Funds
March 13, 2018 09:30 ET
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
December 05, 2017 08:15 ET
|
Galectin Therapeutics Inc.
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line...
Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
December 04, 2017 16:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing...
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 16:00 ET
|
ProQR Therapeutics N.V.
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...
Brainsway® Announces Positive Final Results of its Deep TMS Multicenter Study in Obsessive Compulsive Disorder (OCD) Patients
June 12, 2017 12:35 ET
|
Brainsway Ltd.
Brainsway will prepare a submission to the FDA to market the device for OCD Deep TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD Patients...